---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References"
description: "Reference list for the formulary evidence report on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer. 161 cited documents."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References

<a id="references"></a>

## 5 References

1. [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)
2. [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)
3. [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)
4. [Balar et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34051177/)
5. [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)
6. [Bhanvadia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33820747/)
7. [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)
8. [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)
9. [Boorjian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7988888/)
10. [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)
11. [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)
12. [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and)
13. [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)
14. [CG Oncology CORE-001 Nature Medicine publication press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-nature-medicine-publication-final-results)
15. [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)
16. [CG Oncology expanded access program press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-initiates-expanded-access-program-cretostimogene)
17. [CG Oncology Fast Track and Breakthrough Therapy press release (2023)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-receives-both-fda-fast-track-and-breakthrough)
18. [CG Oncology first-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-first-quarter-2026-financial-results-and)
19. [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)
20. [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)
21. [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)
22. [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)
23. [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)
24. [CG Oncology prospectus (2024)](https://www.sec.gov/Archives/edgar/data/1991792/000119312524015534/d551455d424b4.htm)
25. [CG Oncology SUO 2025 data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/new-cretostimogene-grenadenorepvec-data-highlight-its-potential)
26. [CG Oncology third-quarter 2025 results press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2025-financial-results-and)
27. [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)
28. [Chamie et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3773281/)
29. [Chamie et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38226931/)
30. [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/)
31. [Chang et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12708036/)
32. [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/)
33. [Chevuru et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36456454/)
34. [Chun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11221414/)
35. [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)
36. [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)
37. [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)
38. [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)
39. [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)
40. [ClinicalTrials.gov NCT04752722](https://clinicaltrials.gov/study/NCT04752722)
41. [ClinicalTrials.gov NCT06211764](https://clinicaltrials.gov/study/NCT06211764)
42. [ClinicalTrials.gov NCT06443944](https://clinicaltrials.gov/study/NCT06443944)
43. [ClinicalTrials.gov NCT07283835](https://clinicaltrials.gov/study/NCT07283835)
44. [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)
45. [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)
46. [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)
47. [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)
48. [Cohen (2026)](https://cgoncology.com/wp-content/uploads/2026/10/SUNA_2026_Cretostimogene_Optimized_Administration_Podium.pdf)
49. [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)
50. [Cooper et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9897878/)
51. [D'Andrea et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39550339/)
52. [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)
53. [de Jong et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10572776/)
54. [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf)
55. [Dinney et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_and_Cytokines_Poster.pdf)
56. [Dinney et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_CORE-008_CohortA_and_PK_PD_Poster.pdf)
57. [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)
58. [eCQI CMS646v6 Intravesical BCG for NMIBC (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0646v6)
59. [enGene LEGEND Cohort 1 and BLA plan press release (2026)](https://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspx)
60. [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)
61. [Faraj et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32482512/)
62. [Farré et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40947056/)
63. [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)
64. [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)
65. [FDA nogapendekin alfa inbakicept-pmln expanded indication notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle)
66. [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet)
67. [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)
68. [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)
69. [Griebsch et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12647504/)
70. [Haas et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26807928/)
71. [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)
72. [Herr et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25813144/)
73. [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)
74. [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf)
75. [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)
76. [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)
77. [Jazayeri et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41421932/)
78. [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)
79. [Jung et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29863576/)
80. [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)
81. [Kamat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10713193/)
82. [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)
83. [Kates et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712383/)
84. [Kissei Pharmaceutical Lancet Oncology publication press release (2026)](https://www.kissei.co.jp/news/uploaded/ac0d28038b8ced3e28ffd15df1f1d731.pdf)
85. [Kurnot and Kaye (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560494/)
86. [Lenis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33201207/)
87. [Lerner et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4720147/)
88. [Li et al. (2021)](https://cgoncology.com/wp-content/uploads/2025/11/2021_sitc_core-001_poster-1.pdf)
89. [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)
90. [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)
91. [Li et al. (2024b)](https://cgoncology.com/wp-content/uploads/2025/11/REQ082_ASCO_2024_Roger-Li_CORE-001_Final_Website.pdf)
92. [Lindskrog et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8052448/)
93. [Lotan et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SCSAUA_Lotan_007_Clinical-Trials-Demographics-1-1.pdf)
94. [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)
95. [Marqueen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349610/)
96. [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)
97. [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)
98. [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)
99. [Merck TICE BCG HCP letter (2026)](https://www.auanet.org/documents/about/Annual%20HCP%20Letter%20TICE%20BCG%20September%202026%20%28AUA%29.pdf)
100. [MHLW orphan regenerative medical product designation (2025)](https://www.pref.nara.jp/secure/307355/06314.pdf)
101. [Miyake et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41386721/)
102. [Mohamed et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33423864/)
103. [Mokkapati (2025)](https://cgoncology.com/wp-content/uploads/2025/11/A0793_Mokkapati_EAU-2025_BOND-003-and-CORE-001-Convergent_Final-V7-1.pdf)
104. [Mossanen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30446799/)
105. [Moyer et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721500/)
106. [Moyer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13360992/)
107. [Myers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993341/)
108. [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)
109. [Nadelmann et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42143549/)
110. [Narayan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721637/)
111. [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)
112. [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1)
113. [Nature Medicine CORE-001 article Table 2 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/2)
114. [Nature Medicine CORE-001 author correction (2024)](https://www.nature.com/articles/s41591-024-03137-w)
115. [Nature Medicine CORE-001 publisher correction (2024)](https://www.nature.com/articles/s41591-024-03157-6)
116. [Nayak et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261437/)
117. [Necchi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38740030/)
118. [Nemunaitis et al. (2008)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)40090-0)
119. [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)
120. [Pinton et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13464600/)
121. [Presicce et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8217047/)
122. [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)
123. [Raj et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17382713/)
124. [Rieger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38491799/)
125. [Robesti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508430/)
126. [Scilipoti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39730299/)
127. [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)
128. [Senzer et al. (2006)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(06)00324-8)
129. [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)
130. [Shimko et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21168867/)
131. [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41687978/)
132. [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)
133. [Steinberg et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31821066/)
134. [Steinberg et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/02/F13_BOND-003-Cohort-C-Cystectomy_Gary-Steinberg_Final.pdf)
135. [Su et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39210627/)
136. [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)
137. [Svatek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24472711/)
138. [Sylvester et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16442208/)
139. [Sylvester et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33419683/)
140. [Tan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10334230/)
141. [Tan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42869744/)
142. [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)
143. [Taylor et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/39694798/)
144. [Tyson (2025a)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_C_Late-Breaking_Plenary.pdf)
145. [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)
146. [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)
147. [Tyson et al. (2025c)](https://cgoncology.com/wp-content/uploads/2025/11/SIU_TIPs_Bond-003-Cohort-P_Poster_Final-1.pdf)
148. [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)
149. [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)
150. [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)
151. [Uchio et al. (2021)](https://cgoncology.com/wp-content/uploads/2025/11/2021_sitc_bond-003_poster-2.pdf)
152. [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)
153. [WHO proposed INN List 127 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf)
154. [WHO recommended INN List 89 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl89.pdf)
155. [Williams et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8013821/)
156. [Williams et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40122296/)
157. [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)
158. [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/)
159. [Yang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33543424/)
160. [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)
161. [Zhang and Qi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11317044/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
